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First ebola vaccine approved
The world's first vaccine against Ebola virus gained conditional approval from the European Commission in November. Merck's Ervebo vaccine has already been given to hundreds of thousands of people to help control the current outbreak in the Democratic Republic of the Congo (DRC). The approval will now speed up licensing by African country regulators and enable rapid patient access in at-risk countries.
The vaccine is a vesicular stomatitis virus-based vaccine expressing the glycoprotein of a Zaire Ebola virus (rVSV-ZEBOV). It has been given as one dose during an outbreak to individuals who have been in contact with infected people and the contacts of those contacts, as well as to front-line healthcare workers, in a so-called ring vaccination strategy under an expanded-access compassionate use protocol. Preliminary analysis of 90,000 vaccinated individuals in DRC estimates an efficacy rate of 97.5% when individuals are exposed ten days or more after vaccination, according to World Health Organization (WHO) data.
Another vaccine, made by Johnson & Johnson, began testing in DRC in November. The company in the same month applied for European approval. The Johnson & Johnson vaccine regime consists of two vaccines: an adenovirus type 26-vectored vaccine encoding the glycoprotein of Zaire Ebola virus (Ad26.ZEBOV) and a booster shot with a modified vaccinia Ankara-vectored vaccine encoding glycoproteins and a nucleoprotein from several types of Ebola virus (MVA-BN-Filo) given 56 days after the first immunization. The trial will vaccinate at-risk individuals living close to, but outside, the current outbreak zone in an effort to prevent virus spread.
The WHO says the Merck vaccine meets the organization's quality, safety and efficacy standards, which allows United Nations agencies and the vaccine alliance Gavi to stockpile the vaccine for future outbreaks.
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"We are being whipsawed by a failure to understand a fundamental economic principle." Kenneth Moch, CEO of Cognition Therapeutics, referring to the drug pricing bill before the uS House of Representatives. More than 100 biotech execs penned a letter to the leaders of the uS House of Representatives. (STAT, 5 December 2019)

Grail of RAS cancer drugs within reach
The first KRaS inhibitors to reach the clinic show preliminary but promising safety and efficacy. S everal decades of basic research on RAS signaling in cancer are finally starting to pay dividends. Amgen and Mirati Therapeutics recently reported early clinical data on their respective first-in-class small molecules, AMG-510 and MRTX849, in a range of solid tumors carrying the KRAS G12C mutation. These KRAS inhibitors not only disrupt cancer cell growth but also appear to promote T-cell infiltration into the tumor microenvironment: important first steps in addressing a vast area of cancer biology. But much effort is still needed to embed these agents in durable combination therapies. "Everyone is thinking very strongly in terms of what's next with these, " says Julian Downward, of the London-based Crick Institute. "We have to think ahead. " Tackling other KRAS oncogenic mutations that are also important cancer drivers is still wide open territory. A couple of firms are developing promising approaches to get beyond KRAS G12C , but none of these is yet in the clinic.
Despite the caution, there is a palpable air of excitement among scientists focused on RAS signaling, given that RAS mutations are implicated in about one third of all human cancers. RAS proteins -of which there are three isoforms, KRAS, HRAS and NRAS -have been notoriously difficult to drug because their smooth surfaces lack obvious binding pockets to target with a drug. Although KRAS is the most clinically significant of the three, all are involved in relaying external growth signals to the nucleus through the mitogenactivated protein kinase (MAPK; also known as extracellular signal-regulated kinase, or ERK) pathway or through the phosphatidylinositol-3-OH kinase (PI3K)-AKT-mTOR pathway. The whole cascade is initiated when a ligand binds a receptor tyrosine kinase, leading to RAS activation,
RaS cycles between an 'on' state bound to GTP and an 'off' state bound to GDP. The active and inactive conformations of RaS differ, which controls the interactions between RaS and its binding partners. Credit: Reproduced with permission from Nature Reviews Drug Discovery, Springer nature.
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NAtuRe BioteChNoloGy | VOL 38 | JanuaRy 2020 | 3-8 | www.nature.com/naturebiotechnology followed by the recruitment and activation of RAF kinases, which then relay the signal either through MEK -another kinase in the cascade -and MAPK or through PI3K. The RAS proteins function as molecular switches, cycling between active 'on' and inactive 'off ' states. In its active state, RAS is bound to a guanosine triphosphate (GTP) molecule, which it then hydrolyzes to GDP, triggering the adoption of the inactive, GDPbound conformation. When RAS genes have missense gain-of-function mutations, these favor the 'always-on' RAS conformation, which leads to aberrant growth signaling and uncontrolled cell division. KRAS mutations are associated with 95% of pancreatic cancers, 45% of colorectal cancers and 35% of lung cancers.
The KRAS G12C mutation is one of several important cancer-causing mutations, and although it has become the focus of present drug development efforts, is not the most prevalent. The simple reason drug developers targeted it initially was because they could. Until then, KRAS had defied all attempts to develop competitive inhibitors due to its ultra-high affinity for its substrate, GTP. But Kevan Shokat, of the University of California, San Francisco, used a fragment-based screening approach to pry open the KRAS G12C protein by finding an allosteric binding pocket, separate from its active site, which provided access to small-molecule inhibitors. The mechanism is indirect -the pocket is only accessible on inactive GDP-bound KRAS G12C -and relies on cycling between the active and inactive states. The inhibitors lock KRAS G12C into the inactive GDP conformation, resulting in the depletion of GTP-bound active KRAS G12C . The initial leads Shokat and co-workers identified had just millimolar affinity for KRAS G12C , but since then, work by several groups has generated many other highaffinity agents that are in making their way to the clinic (Table 1) .
These agents are exquisitely selective for cells carrying the cancer-causing mutation. Shokat likens the mechanism to those of antibiotics, which interact with bacterial targets only. "To me, it's the first step towards an infectious-disease strategy, where you can be specific for the cell you want to kill, " says Shokat, who is a cofounder of both Wellspring Biosciences, which has an alliance with the Janssen Biotech arm of Johnson & Johnson on a clinical-stage KRAS G12C inhibitor, and Revolution Medicines, which is developing a panel of preclinical molecules for a range of KRAS mutations.
KRAS inhibitors appear to operate by a dual mechanism that involves both direct killing of KRAS-mutated cancer cells and indirect killing mediated by an immune response directed against the cancer. The latter mechanism has, so far, been reported from preclinical studies in mice only. Scientists from Amgen and academic partners reported that AMG-510 created a pro-inflammatory milieu in the tumor microenvironment and, when combined with a programmed cell death 1 (PD-1) inhibitor, led to durable cures and to protection against subsequent challenge with tumor cells from the same cell line, with or without mutations. If either therapy was administered alone, those responses were not observed, suggesting that KRAS G12C inhibition may improve responses to anti-PD-1 agents. Some researchers had anticipated this might be the case. "There was reason to think RAS was suppressing the immune system locally, " says Downward. A pivotal trial in lung cancer of one such agent, human IgG4 monoclonal antibody nivolumab, suggested that those with KRAS mutations responded more poorly to the drug than those whose cancers were not KRAS-mutated. What's more, his group has reported that RAS boosts production of the immunosuppressive protein PD-1 ligand (PD-L1) by curbing the activity of an mRNA-binding protein, tristetraprolin, which normally keeps PD-L1 expression in check. But the mouse data need to be interpreted cautiously, he says, given that the mouse model used -CT-26 -is known to be overly sensitive to PD-1 inhibition. Whether the same combination would be capable of turning an actual patient's cold tumor hot is another question. "Obviously, it's something worth pursuing, " he says.
Amgen and Mirati both plan to test their respective compounds in combination with PD-1 or PD-L1 inhibitors, as well as with several other agents. Although a potentially important addition to the oncology armamentarium, KRAS G12C inhibitors are unlikely to be deployed as monotherapies. "Tumor resistance will arise, there is no doubt about it, " says Channing Der, of the University of North Carolina, Chapel Hill, who is a scientific adviser to Mirati. "The beauty and curse of these inhibitors is they target mutant RAS, " he says. "Wild-type RAS is going to be activated by these resistance mechanisms, and these inhibitors won't touch them. " Blocking KRAS G12C -driven MAPK signaling will lead to the loss of MAPK-dependent negative feedback loops, he says, which will result in increased activation of signal nodes located upstream of the RAS signal cascade and more signaling through wild-type KRAS.
To prevent this, some companies are pursing so-called 'pan-RAS' inhibitors. These agents have attracted much attention because of their potential to switch off all RAS signaling by hitting targets at the top of the signal cascade. Src homology region 2 domain-containing phosphatase-2 (SHP-2) and son of sevenless homolog 1 (SOS1) are two of the key targets. Amgen has entered a collaboration with Revolution Medicines to test AMG-510 and the latter firm's SHP-2 inhibitor RMC-4630. Mirati and Novartis are similarly testing a combination of MRTX849 and the latter firm's SHP-2 inhibitor TNO155. Boehringer Ingelheim is testing a SOS1 Concerns about their likely toxicity persist, however. "At the moment, I remain unconvinced about where the therapeutic index comes from. You're targeting all cells that use those pathways, " says Downward. Revolution Medicines CEO Mark Goldsmith says his company has already established that MEK inhibition and SHP-2 inhibition are highly synergistic in preclinical models. "The onus is on us to demonstrate that kind of activity in patients, " says Goldsmith. Other potential combination candidates include mammalian target of rapamycin (mTOR) inhibitors and insulin-like growth factor receptor inhibitors. "RAS inhibitors can combine quite well with mTOR inhibitors in terms of growth inhibition, " says Downward. "It's very clear that IGF-1 [insulin-like growth factor 1] signaling is important in cancer generally. " Important as KRAS G12C is -particularly in lung adenocarcinomas, where it occurs in about 13% of cases -it is not the most prevalent oncogenic KRAS mutation. "G12D and G12V are number one and number two in terms of frequency, " Der says. Revolution Medicines is also taking a lead in getting beyond the KRAS G12C mutation. Revolution Medicines is employing a novel KRAStargeting technology that allows it to address the three key mutational hotspots on KRAS, at positions 12, 13 and 61. Each can be substituted by half a dozen different amino acids. "The vast majority of oncogenic KRAS mutations that cause human cancer are at one of those hotspots, " Goldsmith says. "They all happen to be very close to each other. " The approach was originally developed at Warp Drive Bio, which Revolution Medicines acquired in October 2018. It exploits a binding interaction between an immunosuppressive natural product, sanglifehrin A, and cyclophilin A, an abundant chaperone protein involved in protein folding. By attaching different chemical groups to the cyclophilin-A binding moiety of sanglifehrin A, Revolution Medicines can generate composite surfaces that can engage different RAS mutations and block their interaction with RAF. The company's inhibitors bind the GTP-bound active form of RAS, which, it claims, makes them less susceptible to resistance driven by upstream pathway activation. Revolution has yet to disclose when it will move any of its 'KRAS(ON)' inhibitors into the clinic, but Moderna and its partner Merck are already in the clinic with a therapeutic vaccine that targets several KRAS mutations, and Mirati is about to enter Investigational New Drugenabling studies with a KRAS G12D inhibitor. The race to drug KRAS -in all its formsis now on. ❐
Cormac Sheridan
Dublin, Ireland
Published online: 9 January 2020 https://doi.org/10.1038/s41587-019-0382-x
Around the world in a month
Published online: 9 January 2020 https://doi.org/10.1038/s41587-019-0378-6 NETHERLANDS Amsterdam-based sustainable chemistry company Avantium opens a plant to demonstrate monoethylene glycol (MEG) production from plant feedstock. 99% of MEG, a compound used in plastics manufacturing, comes from the petrochemical industry. Avantium claims its technology could reduce carbon emissions 70% compared with traditional MEG production.
PARAGUAY
The country's agriculture regulator approves a drought-and herbicide-tolerant HB4 soybean developed by Argentina-based Verdeca. The biotech soybean now has regulatory approval in more than 80% of the global soybean market, including the US, Argentina and Brazil, and is under consideration in China.
BRAZIL
The country's health service approves a blood test that can detect Zika in less than four hours, compared with other diagnostics' wait of 15-30 days. The test, developed at the University of São Paulo, is 92-100 % accurate, even in patients who have had other mosquito-borne diseases such as dengue fever, yellow fever and chikungunya.
GERMANY
Takeda opens its first vaccine plant outside Japan to manufacture its dengue fever prevention treatment, currently in phase 3 trials. The €130 ($144) million plant in Singen incorporates state-of-the-art automation and expects to employ 200 skilled workers. 
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